Case report: High-grade serous tubo-ovarian carcinoma with FGFR2::IQCG fusion and insights into targetability

By sjmartinez • January 6, 2025

Sono R, Konecny GE, Zhang L. Case report: High-grade serous tubo-ovarian carcinoma with FGFR2::IQCG fusion and insights into targetability. Front Oncol. 2024 Dec 20;14:1514471. doi: 10.3389/fonc.2024.1514471. PMID: 39759134; PMCID: PMC11695219.

Tags: Case report, FGFR2, FGFR2::IQGC, Hematology/Oncology, high-grade serous tubo-ovarian cancer, novel fusion, Publications

Related Posts

Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trial

Abrisqueta P, Karimi YH, Morillo D, Cordoba R, Phillips T, De Vos S, Nijland M, Offner F, Andersson PO, Brody J, Cheah CY, Prieto PG,[...]

Neoadjuvant BO-112 and hypofractionated radiation therapy with or without nivolumab in soft tissue sarcoma: preclinical and phase 1 results

Deng J, Pal A, Testa S, Xu JW, Tran LM, Graham DS, Hargil A, Subramanian A, Campbell KM, Limsuwannarot S, Chumpitaz Lavalle Á, Chin SC,[...]

Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC post-progression on first-line osimertinib: ORCHARD

Riess JW, Yu HA, Le X, de Langen AJ, Cho BC, Piotrowska Z, Hendriks LEL, Morabito A, Bonanno L, Brustugun OT, Halvorsen TO, Kim YJ,[...]